As a selective estrogen-receptor modulator (SERM), TAM is approved by the Food and Drug Administration (FDA) to treat both early and advanced ER-positive breast cancer in pre- and post-menopausal women, and recommended for 10 years to reduce the incidence of breast cancer [2]. This evidence concerns the gene ESR1 and breast carcinoma.